Though it is very difficult to predict resistance to EGFR-TKI before EGFR-TKI therapy and then PFS and OS after EGFR-TKI treatment because of MET gene activation, theremay still be a substantial clinical benefit for assessing MET FISH status in NSCLC patients with EGFR gene mutations especially before initiation of EGFR-TKI therapy. Here, MET is linked to non-small cell lung carcinoma.